vs
Sotera Health Co（SHC）与VIEMED HEALTHCARE, INC.（VMD）财务数据对比。点击上方公司名可切换其他公司
Sotera Health Co的季度营收约是VIEMED HEALTHCARE, INC.的4.0倍（$303.4M vs $76.2M）。Sotera Health Co净利率更高（11.5% vs 7.4%，领先4.1%）。VIEMED HEALTHCARE, INC.同比增速更快（25.5% vs 4.6%）。Sotera Health Co自由现金流更多（$52.4M vs $9.7M）。过去两年VIEMED HEALTHCARE, INC.的营收复合增速更高（22.7% vs 10.6%）
Sotera Health Co是全球领先的医疗安全解决方案提供商，面向医疗器械厂商、制药企业、食品及消费品公司提供灭菌服务、实验室分析检测与合规咨询支持，帮助客户满足监管要求，保障上市产品的使用安全。
Viemed Healthcare是一家专注于呼吸护理解决方案的医疗科技企业，研发、生产及销售便携式呼吸机、呼吸治疗设备及配套支持服务，覆盖北美、欧洲及亚太核心市场的急症、亚急症及居家护理场景，服务急慢性呼吸系统疾病患者。
SHC vs VMD — 直观对比
营收规模更大
SHC
是对方的4.0倍
$76.2M
营收增速更快
VMD
高出21.0%
4.6%
净利率更高
SHC
高出4.1%
7.4%
自由现金流更多
SHC
多$42.7M
$9.7M
两年增速更快
VMD
近两年复合增速
10.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $303.4M | $76.2M |
| 净利润 | $34.8M | $5.6M |
| 毛利率 | 54.7% | 57.9% |
| 营业利润率 | 23.2% | 11.0% |
| 净利率 | 11.5% | 7.4% |
| 营收同比 | 4.6% | 25.5% |
| 净利润同比 | 182.8% | 30.7% |
| 每股收益（稀释后） | $0.12 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SHCVMD
| Q4 25 | $303.4M | $76.2M | ||
| Q3 25 | $311.3M | $71.9M | ||
| Q2 25 | $294.3M | $63.1M | ||
| Q1 25 | $254.5M | $59.1M | ||
| Q4 24 | $290.2M | $60.7M | ||
| Q3 24 | $285.5M | $58.0M | ||
| Q2 24 | $276.6M | $55.0M | ||
| Q1 24 | $248.2M | $50.6M |
净利润SHCVMD
| Q4 25 | $34.8M | $5.6M | ||
| Q3 25 | $48.4M | $3.5M | ||
| Q2 25 | $8.0M | $3.2M | ||
| Q1 25 | $-13.3M | $2.6M | ||
| Q4 24 | $12.3M | $4.3M | ||
| Q3 24 | $17.0M | $3.9M | ||
| Q2 24 | $8.8M | $1.5M | ||
| Q1 24 | $6.3M | $1.6M |
毛利率SHCVMD
| Q4 25 | 54.7% | 57.9% | ||
| Q3 25 | 57.0% | 57.5% | ||
| Q2 25 | 56.6% | 58.3% | ||
| Q1 25 | 53.2% | 56.3% | ||
| Q4 24 | 56.6% | 59.5% | ||
| Q3 24 | 55.4% | 59.3% | ||
| Q2 24 | 55.2% | 59.8% | ||
| Q1 24 | 51.2% | 58.9% |
营业利润率SHCVMD
| Q4 25 | 23.2% | 11.0% | ||
| Q3 25 | 23.4% | 7.8% | ||
| Q2 25 | 6.4% | 8.1% | ||
| Q1 25 | -5.8% | 6.5% | ||
| Q4 24 | 30.0% | 10.6% | ||
| Q3 24 | 28.2% | 9.7% | ||
| Q2 24 | 27.8% | 6.6% | ||
| Q1 24 | 21.4% | 4.4% |
净利率SHCVMD
| Q4 25 | 11.5% | 7.4% | ||
| Q3 25 | 15.5% | 4.9% | ||
| Q2 25 | 2.7% | 5.0% | ||
| Q1 25 | -5.2% | 4.4% | ||
| Q4 24 | 4.2% | 7.1% | ||
| Q3 24 | 6.0% | 6.7% | ||
| Q2 24 | 3.2% | 2.7% | ||
| Q1 24 | 2.5% | 3.2% |
每股收益（稀释后）SHCVMD
| Q4 25 | $0.12 | $0.14 | ||
| Q3 25 | $0.17 | $0.09 | ||
| Q2 25 | $0.03 | $0.08 | ||
| Q1 25 | $-0.05 | $0.06 | ||
| Q4 24 | $0.05 | $0.10 | ||
| Q3 24 | $0.06 | $0.10 | ||
| Q2 24 | $0.03 | $0.04 | ||
| Q1 24 | $0.02 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $344.6M | $13.5M |
| 总债务越低越好 | $2.1B | — |
| 股东权益账面价值 | $606.0M | $141.5M |
| 总资产 | $3.3B | $199.2M |
| 负债/权益比越低杠杆越低 | 3.53× | — |
8季度趋势，按日历期对齐
现金及短期投资SHCVMD
| Q4 25 | $344.6M | $13.5M | ||
| Q3 25 | $299.2M | $11.1M | ||
| Q2 25 | $332.4M | $20.0M | ||
| Q1 25 | $304.4M | $10.2M | ||
| Q4 24 | $277.2M | $17.5M | ||
| Q3 24 | $306.7M | $11.3M | ||
| Q2 24 | $246.1M | $8.8M | ||
| Q1 24 | $261.1M | $7.3M |
总债务SHCVMD
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — |
股东权益SHCVMD
| Q4 25 | $606.0M | $141.5M | ||
| Q3 25 | $550.5M | $133.6M | ||
| Q2 25 | $511.3M | $139.7M | ||
| Q1 25 | $414.1M | $134.8M | ||
| Q4 24 | $404.9M | $131.4M | ||
| Q3 24 | $470.2M | $125.0M | ||
| Q2 24 | $422.8M | $119.4M | ||
| Q1 24 | $429.4M | $116.3M |
总资产SHCVMD
| Q4 25 | $3.3B | $199.2M | ||
| Q3 25 | $3.2B | $202.4M | ||
| Q2 25 | $3.2B | $184.6M | ||
| Q1 25 | $3.1B | $178.1M | ||
| Q4 24 | $3.1B | $177.1M | ||
| Q3 24 | $3.1B | $169.5M | ||
| Q2 24 | $3.1B | $163.9M | ||
| Q1 24 | $3.1B | $154.9M |
负债/权益比SHCVMD
| Q4 25 | 3.53× | — | ||
| Q3 25 | 3.89× | — | ||
| Q2 25 | 4.34× | — | ||
| Q1 25 | 5.36× | — | ||
| Q4 24 | 5.49× | — | ||
| Q3 24 | 4.73× | — | ||
| Q2 24 | 5.26× | — | ||
| Q1 24 | 5.19× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $103.1M | $18.4M |
| 自由现金流经营现金流 - 资本支出 | $52.4M | $9.7M |
| 自由现金流率自由现金流/营收 | 17.3% | 12.7% |
| 资本支出强度资本支出/营收 | 16.7% | 11.5% |
| 现金转化率经营现金流/净利润 | 2.96× | 3.27× |
| 过去12个月自由现金流最近4个季度 | $149.2M | $11.9M |
8季度趋势，按日历期对齐
经营现金流SHCVMD
| Q4 25 | $103.1M | $18.4M | ||
| Q3 25 | $71.2M | $18.4M | ||
| Q2 25 | $57.4M | $12.3M | ||
| Q1 25 | $55.5M | $2.9M | ||
| Q4 24 | $55.7M | $15.0M | ||
| Q3 24 | $97.5M | $12.7M | ||
| Q2 24 | $61.3M | $10.2M | ||
| Q1 24 | $9.7M | $1.2M |
自由现金流SHCVMD
| Q4 25 | $52.4M | $9.7M | ||
| Q3 25 | $35.0M | $10.7M | ||
| Q2 25 | $26.2M | $4.1M | ||
| Q1 25 | $35.6M | $-12.6M | ||
| Q4 24 | $-10.2M | $3.2M | ||
| Q3 24 | $61.1M | $1.7M | ||
| Q2 24 | $19.4M | $1.2M | ||
| Q1 24 | $-25.2M | $-4.8M |
自由现金流率SHCVMD
| Q4 25 | 17.3% | 12.7% | ||
| Q3 25 | 11.2% | 14.9% | ||
| Q2 25 | 8.9% | 6.5% | ||
| Q1 25 | 14.0% | -21.4% | ||
| Q4 24 | -3.5% | 5.2% | ||
| Q3 24 | 21.4% | 3.0% | ||
| Q2 24 | 7.0% | 2.3% | ||
| Q1 24 | -10.2% | -9.5% |
资本支出强度SHCVMD
| Q4 25 | 16.7% | 11.5% | ||
| Q3 25 | 11.6% | 10.6% | ||
| Q2 25 | 10.6% | 12.9% | ||
| Q1 25 | 7.8% | 26.2% | ||
| Q4 24 | 22.7% | 19.5% | ||
| Q3 24 | 12.7% | 19.0% | ||
| Q2 24 | 15.2% | 16.3% | ||
| Q1 24 | 14.1% | 11.9% |
现金转化率SHCVMD
| Q4 25 | 2.96× | 3.27× | ||
| Q3 25 | 1.47× | 5.23× | ||
| Q2 25 | 7.21× | 3.88× | ||
| Q1 25 | — | 1.09× | ||
| Q4 24 | 4.52× | 3.47× | ||
| Q3 24 | 5.73× | 3.29× | ||
| Q2 24 | 7.00× | 6.94× | ||
| Q1 24 | 1.53× | 0.73× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SHC
| Transferred At Point In Time | $198.4M | 65% |
| Nelson Labs | $55.2M | 18% |
| Nordion | $49.8M | 16% |
VMD
暂无分部数据
